Coverage of arthritis in the United States focuses on clinical research, joint health studies, pain management techniques and treatment breakthroughs. This reporting follows findings from medical professionals and health organizations.
A retrospective study of patients starting GLP-1 drugs found greater weight loss tracked with larger gains in patient-reported outcomes.
Live Poll
Would you expect losing weight on GLP-1 drugs to ease your arthritis pain?
November 8, 2026
AI Model Tests 1,758 CAR T-Cell BindersCHAI president Brian Anderson outlined AI's role in rheumatology and CAR T-cell design at ACR Convergence.
November 7, 2026
Journavx Linked to Fewer Opioid Prescriptions After Knee SurgeryA retrospective study presented at a surgical meeting found patients given Journavx after knee replacement were less likely to fill opioid prescriptions.
November 7, 2026
J&J Pill Eases Psoriatic Arthritis SymptomsA late-stage trial found once-daily icotrokinra improved joint symptoms more than placebo in adults with active psoriatic arthritis.
November 6, 2026
Women With Polymyalgia Rheumatica Face Higher Steroid ExposureA US retrospective cohort study found women received higher cumulative glucocorticoid doses than men over three years of treatment.
November 6, 2026
Pickleball Injuries Surge in ER VisitsEmergency department visits for pickleball musculoskeletal injuries in the United States rose sharply over an 11-year period, according to a new study.
November 5, 2026
Osteal Presents Infection Treatment Data at AAHKSOsteal Therapeutics will present three scientific studies on periprosthetic joint infection treatment at the 2026 AAHKS Annual Meeting in Texas.
November 5, 2026
FDA Clears Forward's FT2109 Psoriatic Arthritis TrialForward Therapeutics received U.S. clearance for a Phase 2 proof-of-concept study of its oral TNF signaling inhibitor, FT2109, in active psoriatic arthritis.
November 5, 2026
Screening Tool Boosts Psoriatic Arthritis DetectionA single-center dermatology study found routine screening identified psoriatic arthritis in most patients with psoriasis who were evaluated.
November 4, 2026
Spyre Drops Rheumatic Program After Trial SetbacksSpyre Therapeutics halted SPY072 development in rheumatic diseases after sub-studies missed primary endpoints, while advancing the drug in a hidradenitis suppurativa combination trial.
November 4, 2026
Oral Prednisone Speeds Uveitis Inflammation ControlA retrospective study of 462 patients links oral prednisone added to eye drops with faster control of HLA-B27-associated uveitis inflammation.
This section follows clinical trial outcomes, new pharmacological treatments, lifestyle intervention research and data on the prevalence of chronic joint conditions. It reaches every state and the various care systems that patients navigate for support. Arthritis management often changes due to shifts in insurance coverage or the emergence of new diagnostic tools that allow for earlier intervention. Chronic pain management remains the most persistent challenge reported in the context of these long-term conditions.
